Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Killer-cell dominance dichotomy governs tumor immune networks and stratifies inflamed cancers

Created on 20 Jun 2026

Authors

Li, A.-N., Yu, Z., Zhang, W., Chang, H., Feng, S., Yang, X., Xiong, K., He, L., Zhao, Z., Shen, L., Tan, Z., Du, W., Zhong, L., Zhang, X., Hu, Y., Su, X., Wang, R., Fu, S., Zhang, L., Hong, S.

Abstract

Cancer immunotherapy benefits remain limited, even among hot tumors with high killer lymphocyte infiltration. Here, we investigated the population-level architecture of killer cells based on nearly 5,000 pan-cancer scRNA-seq samples, together with orthogonal validation by spectral cytometry and spatial transcriptomics. Unlike the prevailing hot-cold paradigm, which assumes coordinated infiltration of multiple cytotoxic lineages, we uncovered a conserved framework wherein terminal cytotoxic immunity in individuals or malignancies diverges into states dominated by either exhausted CD8+ T cells (Tex) or CD56dimCD16hi NK (NK1) cells. Despite the complexity of the tumor microenvironment, Tex-NK1 divergence governs the primary axis of tumor-intrinsic and tumor-extrinsic variance. Distinct from the conventional view that NK cells positively contribute to immunotherapy efficacy, NK1-skewed tumors, although highly cytolytic, are refractory to current immune checkpoint blockade regimens. This killer divergence defines a foundational axis of cancer immunity and provides a resource for prioritizing next-generation targets for NK-directed immunotherapy.

Preprint server: bioRxiv
The authors list and abstract were imported from bioRxiv on 20 Jun 2026.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this preprint? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 1
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement